<div id="readability-page-1"><p>Analyst Brendan Smith of TD Cowen maintained a Buy rating on Halozyme, retaining the price target of $96.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Brendan Smith has given his Buy rating due to a combination of factors that highlight Halozyme’s strong and durable growth profile. He points to a robust first quarter, marked by materially higher royalty and total revenues than market expectations, driven by key ENHANZE-based products and strong operating leverage that lifted earnings meaningfully above Street estimates.</p> <p>He also emphasizes the new $1B share repurchase authorization, with a significant portion slated for 2026, as a clear signal of management’s confidence in both near-term performance and the longevity of the royalty model, especially since current guidance does not yet reflect any buyback benefit. With a long runway of potential ENHANZE launches into the next decade, reinforced by proprietary scenario work, he maintains that the stock’s top- and bottom-line growth prospects remain underappreciated, supporting his unchanged $96 price target and Buy recommendation.</p> <p>Smith covers the Healthcare sector, focusing on stocks such as Halozyme, Codexis, and Repligen. According to TipRanks, Smith has an average return of <span>5.3%</span> and a 43.32% success rate on recommended stocks. </p> <p>In another report released on May 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $95.00 price target.</p></div>

HALO

SBIO

IBBQ

LABU

<p>Analyst Brendan Smith of TD Cowen has reiterated a Buy rating on Halozyme, maintaining a price target of $96. He cites strong growth driven by ENHANZE-based products and a new $1B share repurchase authorization as indicators of management's confidence. Smith believes the stock's growth potential is underappreciated, supported by robust first-quarter results and a long runway for future ENHANZE launches. H.C. Wainwright also supports this view with a Buy rating and a $95 price target.</p>

Tip Ranks

Halozyme Therap

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Codexi

Repligen

Analyst Reiterates Buy on Halozyme, Citing Underappreciated Growth and Maintaining $96 Price Target